Thematic photoMartin FalbisonerCC BY-SA 3.0Resized, encoded as WebP; displayed with responsive cropping under the original licenceSEC EDGAR published this disclosure on 2026-08-10. Read the original document for its full text and supporting detail.
Open the original document at SEC EDGAR ↗accession0002143905-26-000003
acquired disposedA
codeC
direct or indirectI
form4
is derivativefalse
issuer nameBlossomHill Therapeutics, Inc.
labelConversion of derivative
Source record & verificationDates, provenance and technical details
Context
links are based on the recorded entity typeRecorded payloadStructured source data
Recorded payload
JSON payload as stored after parsing{
"accession": "0002143905-26-000003",
"acquired_disposed": "A",
"code": "C",
"direct_or_indirect": "I",
"form": "4",
"is_derivative": false,
"issuer_name": "BlossomHill Therapeutics, Inc.",
"label": "Conversion of derivative",
"person_name": "Liptak Vincent Paul",
"price": null,
"role": "General Counsel",
"security": "Common Stock",
"shares": 22687,
"shares_owned_after": 22687,
"source_path": "edgar/data/1839970/0002143905-26-000003.txt",
"ticker": "BLSM",
"transaction_date": "2026-08-10",
"value": null
}Evidence-based analysis
facts, provenance and explicit model coverageDescriptive evidence from the stored source record; it is not advice, a forecast or a legal conclusion.